Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. September 2014 09:00 ET | Quelle: PharmaCyte Biotech, Inc.

Nuvilex's Partner, Austrianova, Publishes Scientific Review Article Emphasizing Use of Cell-in-a-Box(R) for Treatment of Diabetes

SILVER SPRING, Md., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases,...
18. September 2014 10:49 ET | Quelle: PharmaCyte Biotech, Inc.

Nuvilex Updates Shareholders on Recent Activities and Discusses Future Plans for Development of Treatments for Cancer and Diabetes

SILVER SPRING, Md., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today...
05. September 2014 13:22 ET | Quelle: PharmaCyte Biotech, Inc.

Nuvilex's Partner, Austrianova, Receives Prestigious Emerging Enterprises 2014 Best Innovation Award in Singapore

SILVER SPRING, Md., Sept. 5, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of...
02. September 2014 09:00 ET | Quelle: PharmaCyte Biotech, Inc.

Nuvilex Submits Application for Orphan Drug Designation to the European Medicines Agency for Its Cell-in-a-Box(R) Treatment for Pancreatic Cancer

SILVER SPRING, Md., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of...
20. August 2014 09:00 ET | Quelle: PharmaCyte Biotech, Inc.

Nuvilex Begins Preclinical Studies With Translational Drug Development to Determine if Nuvilex's Unique Cancer Treatment Can Slow Accumulation of Malignant Ascites Fluid

SILVER SPRING, Md., Aug. 20, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of...
14. August 2014 09:00 ET | Quelle: PharmaCyte Biotech, Inc.

Nuvilex Announces Publication of Combined Results of the Initial Phase 1/2 Clinical Trial and a Second Phase 2 Clinical Trial of the Cell-in-a-Box(R) Plus Ifosfamide Combination in Patients With Advanced, Inoperable Pancreatic Cancer

SILVER SPRING, Md., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of...
13. August 2014 09:00 ET | Quelle: PharmaCyte Biotech, Inc.

Nuvilex Provides Update on Status of Preclinical Studies at Translational Drug Development

SILVER SPRING, Md., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of...
04. August 2014 09:45 ET | Quelle: PharmaCyte Biotech, Inc.

Nuvilex Announces That Dr. Richard M. Hyslop Will Present at the ACS Annual Meeting on "Sustainable, Green Chemistry and Medicine: Targeted Cannabinoid-Based Chemotherapy Utilizing Cell-in-a-Box(R) Live Cell Encapsulation Technology."

SILVER SPRING, Md., Aug. 4, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of...
17. Juli 2014 09:00 ET | Quelle: PharmaCyte Biotech, Inc.

Nuvilex and Austrianova Announce Results of Clinical Trial in Dogs with Mammary Tumors Treated With Cell-in-a-Box(R) Plus Cyclophosphamide

SILVER SPRING, Md., July 17, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of...
14. Juli 2014 09:00 ET | Quelle: PharmaCyte Biotech, Inc.

Nuvilex Provides Shareholder Update on Milestone Accomplishments

SILVER SPRING, Md., July 14, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of...

Vorherige Seite

Nächste Seite